(Q46118866)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21330401%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

title

Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21330401%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21330401%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Jonathan Goldin

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21330401%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

12

T F Cloughesy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21330401%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

author name string

W B Pope

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21330401%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

A Lai

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21330401%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

R Mehta

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21330401%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

H J Kim

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21330401%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

J Qiao

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21330401%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

X Xue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21330401%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

M S Brown

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21330401%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

P L Nghiemphu

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21330401%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

A Tran

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21330401%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

publication date

17 February 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21330401%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Neuroradiology

22 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21330401%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21330401%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21330401%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

page(s)

882-889

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21330401%20AND%20SRC:MED&resulttype=core&format=json

Antiangiogenic therapies for high-grade glioma

22 January 2020

cites work

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2385

Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2385

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2385

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2385

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2385

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2385

Pseudoprogression and pseudoresponse: challenges in brain tumor imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2385

Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2385

Pseudoprogression in glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2385

Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2385

Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2385

Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2385

An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2385

Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2385

Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2385

Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2385

Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2385

Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2385

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2385

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2385

Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2385

Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.3174%2FAJNR.A2385